甲诺丁衍生物和心脏保护作用的合成
1Guangxi Collaborative Innovation Center of Modern Sericulture and Silk, Hechi University.
Chemical & pharmaceutical bulletin
|November 17, 2024
概括
新型的诺尼丁衍生物可以防止心脏损伤. 化合物C4通过PI3K/Akt/Beclin-1通路调节自,显著降低细胞损伤和亡,显示出作为心肌保护药物的潜力.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 心肌缺血-反 (I/R) 损伤是一个重大的临床挑战.
- 福莫诺尼丁 (FMN) 是一种具有潜在治疗功能的天然化合物.
- 开发用于心血管保护的新型FMN衍生品需要调查.
研究的目的:
- 为了设计和合成新型的诺尼丁衍生物.
- 评估它们对抗氧气-葡萄糖剥夺/再氧化 (OGD/R) 诱导的H9C2细胞损伤的保护作用.
- 阐明潜在的分子机制,专注于自调节.
主要方法:
- 新型FMN衍生物的合成.
- 建立一个OGD/R细胞模型来模拟心肌的I/R损伤.
- 细胞活力通过MTT测定进行评估.
- 使用套件和传输电子显微镜评估了亡,心肌酶活性和自.
- 通过西式涂抹分析的与自相关的因子 (PI3K,Akt,Beclin-1,P62,LC3,ATG12) 的蛋白质表达.
主要成果:
- 1-6 (C1-6) 化合物对OGD/R诱导的H9C2细胞损伤表现出保护作用,通常优于FMN.
- 化合物C4表现出最强烈的活性,超过了阳性对照diltiazem.
- C4显著降低了细胞亡,心肌酶释放 (AST,LDH,CK) 和过度的自.
- 通过降低PI3K,Akt,Beclin-1,P62,LC3和ATG12表达的调节,C4调节的自.
结论:
- 化合物C4有效地保护心肌细胞免受OGD/R损伤.
- 通过PI3K/Akt/Beclin-1信号通路调节自,C4发挥其心脏保护作用.
- C4代表了一种新型心肌保护剂的有希望的候选者,为I/R损伤提供了一种新的治疗策略.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.3K
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:16Antianginal Drugs: Nitrates and β-Blockers
525
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
525
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
407
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
407